Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This investigational cell therapy consists of autologous bone marrow mononuclear cells (BMNCs) and is being developed by the Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia (FFIS) for the treatment of amyotrophic lateral sclerosis (ALS). The therapy involves the extraction of a patient's own bone marrow cells, which are then processed and re-administered via intramuscular, intraspinal, or intrathecal routes. The cells are hypothesized to function as 'trophic factor pumps,' providing essential neurotrophic support to maintain the functionality of motor neurons and potentially modulating the local immune environment to slow the neurodegenerative process characteristic of ALS. Clinical evaluation has progressed to Phase II trials focusing on safety and efficacy in slowing disease progression.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on autologous bone marrow mononuclear cells (Fundación para la Formación e Investigación Sanitaria).